{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:02:24Z","timestamp":1777899744112,"version":"3.51.4"},"reference-count":38,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Int. J. Hematol. Oncol."],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.2217\/ijh-2018-0001","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T12:30:22Z","timestamp":1536669022000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Nuclear Transport Inhibition in Acute Myeloid Leukemia: Recent Advances and Future Perspectives"],"prefix":"10.2217","volume":"7","author":[{"given":"Chetasi","family":"Talati","sequence":"first","affiliation":[{"name":"Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra L","family":"Sweet","sequence":"additional","affiliation":[{"name":"Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-646240"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.1.27.27"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1286"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901409"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904544"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7000"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.11.009"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.12.016"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2005.10.057"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-447581"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107946"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403838"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-439166"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-423160"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.01147"},{"issue":"10","key":"e_1_3_2_20_1","first-page":"2129","article-title":"Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line","volume":"55","author":"Mirski SE","year":"1995","unstructured":"Mirski SE, Cole SP. Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res. 55(10), 2129\u20132134 (1995).","journal-title":"Cancer Res."},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0858"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2885"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4040.4040"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.212.212"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-750158"},{"key":"e_1_3_2_26_1","unstructured":"Karyopharm Press Release. Karyopharm annouces results from interim analysis of Phase II OPRA study evaluating selinexor in relapsed\/refractory acute myeloid leukemia. http:\/\/investors.karyopharm.com\/releasedetail.cfm?ReleaseID=1015594."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.5066"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.341.341"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.816.816"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1266.1266"},{"issue":"1","key":"e_1_3_2_31_1","first-page":"1244","article-title":"XPO1 inhibition targets transcriptional vulnerability of FLT3-ITD+D835 double mutant AML through p53 accumulation and inhibition of oncogenic transcription factors: lesson learned from cage sequencing of primary AML cells","volume":"130","author":"Yamatani K","year":"2017","unstructured":"Yamatani K, Tabe Y, Sekihara K et al. XPO1 inhibition targets transcriptional vulnerability of FLT3-ITD+D835 double mutant AML through p53 accumulation and inhibition of oncogenic transcription factors: lesson learned from cage sequencing of primary AML cells. Blood 130(Suppl. 1), 1244 (2017).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_2_32_1","first-page":"1344","article-title":"A Phase I\/II study of selinexor (SEL) with sorafenib in patients (pts) with relapsed and\/or refractory (R\/R) FLT3 mutated acute myeloid leukemia (AML)","volume":"130","author":"Daver N","year":"2017","unstructured":"Daver N, Assi R, Garcia-Manero G et al. A Phase I\/II study of selinexor (SEL) with sorafenib in patients (pts) with relapsed and\/or refractory (R\/R) FLT3 mutated acute myeloid leukemia (AML). Blood 130(Suppl. 1), 1344 (2017).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_2_33_1","first-page":"3312","article-title":"Selinexor maintenance is feasible and tolerable after allogeneic stem cell transplant (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)","volume":"130","author":"Liu H","year":"2017","unstructured":"Liu H, Artz A, Larson RA, Kosuri S, Stock W, Bishop MR. Selinexor maintenance is feasible and tolerable after allogeneic stem cell transplant (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood 130(Suppl. 1), 3312 (2017).","journal-title":"Blood"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0624"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5207"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.145"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.136"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-007013"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041974"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.124"}],"container-title":["International Journal of Hematologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/ijh-2018-0001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:29:17Z","timestamp":1715956157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/ijh-2018-0001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.2217\/ijh-2018-0001"],"URL":"https:\/\/doi.org\/10.2217\/ijh-2018-0001","relation":{},"ISSN":["2045-1393","2045-1407"],"issn-type":[{"value":"2045-1393","type":"print"},{"value":"2045-1407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iijh20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iijh20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"IJH04"}}